Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 9, 2012, Pages 851-855

  Murat, C B ^a   Braga, P B S ^a   Fortes, M A H Z ^a   Bronstein, M D ^a   Correa Giannella M L C ^a   Giorgi, R R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Genomic amplification; PIK3CA proto oncogene; Pituitary adenomas; Somatic mutation

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROLACTIN; PROTEIN KINASE B;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; CLINICAL ARTICLE; ENZYME ACTIVE SITE; EXON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS;

EID: 84865398668     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500115     Document Type: Article

References (37)

1. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, DeLong L, Cheong I, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7: 561-573.
2. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18: 77-82.
3. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
4. Raimondi C, Falasca M. Targeting PDK1 in cancer. Curr Med Chem 2011; 18: 2763-2769.
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
6. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 2005; 12: 423-433.
7. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006; 4: 709-714.
8. Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 2006; 97: 1351-1358.
9. Woenckhaus J, Steger K, Sturm K, Munstedt K, Franke FE, Fenic I. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch 2007; 450: 387-395.
10. Santarpia M, Altavilla G, Margeli M, Cirauqui B, Mesiti M, Cavallari V, et al. PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance. Cancer Invest 2008; 26: 1044-1051.
11. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
12. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006; 12: 5932-5935.
13. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17: 1331-1340.
14. Phillips WA, Russell SE, Ciavarella ML, Choong DY, Montgomery KG, Smith K, et al. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer 2006; 118: 2644-2646.
15. Schonleben F, Allendorf JD, Qiu W, Li X, Ho DJ, Ciau NT, et al. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2008; 36: 168-172.
16. Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M, et al. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer 2009; 16: 301-310.
17. Minamoto T, Mai M, Ronai Z. Environmental factors as regulators and effectors of multistep carcinogenesis. Carcinogenesis 1999; 20: 519-527.
18. Pernick NL, Sarkar FH, Philip PA, Arlauskas P, Shields AF, Vaitkevicius VK, et al. Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians. Pancreas 2003; 26: 28-32.
19. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3: 1221-1224.
20. Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008; 214: 347-356.
21. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007; 13: 1161-1170.
22. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007; 57: 664-671.
23. Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005; 7: R609-R616.
24. Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011; 225: 189-194.
25. Choy E, Hornicek F, Macconaill L, Harmon D, Tariq Z, Garraway L, et al. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 2012; 118: 2905-2914.
26. Ji M, Guan H, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011; 11: 147.
27. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2: 833-849.
28. Zhou XK, Tang SS, Yi G, Hou M, Chen JH, Yang B, et al. RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells. World J Gastroenterol 2011; 17: 3700-3708.
29. Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, et al. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res 2008; 14: 6761-6769.
30. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathwayindependent mechanisms. Nat Med 2011; 17: 1116-1120.
31. Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 2007; 92: 2387-2390.
32. Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res 2009; 69: 7357-7365.
33. Tena-Suck ML, Ortiz-Plata A, de la Vega HA. Phosphatase and tensin homologue and pituitary tumor-transforming gene in pituitary adenomas. Clinical-pathologic and immunohistochemical analysis. Ann Diagn Pathol 2008; 12: 275-282.
34. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 2011; 117: 1399-1408.
35. Suhardja A, Kovacs K, Rutka J. Role of transcription factors in the pathogenesis of pituitary adenomas: a review. J Neurooncol 2001; 55: 185-193.
36. Grossman AB, Korbonits M. Akting and cycling: a tale of the pituitary. Horm Res 2004; 62 (Suppl 3): 117-123.
37. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, et al. A drug targeting only p110alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J 2011; 438: 53-62.